ArticleFrontiers in neurology
The Chinese herbal formula pediatric Anshen Bunao Granules for the treatment of tic disorder: study protocol for a randomized, double-blind, active-controlled trial.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tic disorder (TD) affects 2.68% of children in China. It is classified as a movement disorder, with dysfunction in cortical-striatal-thalamic-cortical circuits implicated in its pathophysiology. Western medical treatments for TD may be associated with adverse reactions and suboptimal adherence in some patients. Pediatric Anshen Bunao Granules (PABG) is an in-house traditional Chinese medicine (TCM) preparation with over 20 years of clinical use for TD, approved by the Guangdong Provincial Drug Administration for use in medical institutions across Guangdong Province. Observational studies have reported effects of PABG; however, high-level evidence remains lacking. This study aims to evaluate the efficacy and safety of PABG in children with TD. Methods: This is a randomized, double-blind, active-controlled, parallel-group trial. A total of 150 children aged 4-16 years with TD (TCM syndrome: Spleen Deficiency with Phlegm Accumulation and Wind-Phlegm Disturbance Syndrome) will be recruited from Shenzhen Traditional Chinese Medicine Hospital, Guangdong Province, China. Eligible participants will be stratified by age group and baseline Yale Global Tic Severity Scale (YGTSS) total score, and randomly allocated at a ratio of 2:2:1 to the low-dose PABG group, high-dose PABG group, or active control group (receiving 5% of the active ingredients to maintain blinding) for 8 consecutive weeks of treatment. Primary outcomes will be the change in YGTSS Total Tic Score (YGTSS-TTS) from baseline to Week 8, and the proportion of participants with a ≥ 30% reduction in YGTSS-TTS at Week 8. Secondary outcomes will be assessed using the YGTSS, the TCM Syndrome Rating Scale (TCM-SRS), and the Gilles de la Tourette Syndrome-Quality of Life Scale for Children and Adolescents (C&A-GTS-QoL). Safety assessments will include vital signs, physical examination, laboratory tests, ECG, and adverse events. Discussion: This trial will provide evidence on the efficacy and safety of PABG for children with TD. The findings may inform clinical application and potential registration of this in-house TCM preparation. Clinical trial registration: https://itmctr.ccebtcm.org.cn/, ITMCTR2025001659.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.